P3. Viral studies (natural history and therapeutic)
Oral Abstract Submission
Angelique Eleni. Boutzoukas, MD
Resident
Nationwide Children's Hospital
Columbus, OH
Disclosure: Nothing to disclose
Daniel Freedman, DO
Pediatric Neurology Fellow
Nationwide Children's Hospital
Columbus, OH
Disclosure: Nothing to disclose
W. Garrett Hunt, MD
Associate Professor of Pediatrics
Nationwide Children's Hospital
Columbus, OH
Disclosure: Nothing to disclose
Kathleen A. Mack, SV (ASCP)
Specialist III
Nationwide Children's Hospital
Blacklick, OH
Disclosure: Nothing to disclose
Vedat Yildiz, MS
Biostatistician
Nationwide Children's Hospital
Columbus, OH
Disclosure: Nothing to disclose
Melissa Chung, MD
Clinical Assistant Professor
Nationwide Children's Hospital
Columbus, OH
Disclosure: Nothing to disclose
Jamie Twanow, MD
Assistant Professor of Pediatrics
Nationwide Children's Hospital
Columbus, OH
Disclosure: Nothing to disclose
Emily de los Reyes, MD
Clinical Professor of Pediatrics and Neurology
Nationwide Children's Hospital
Columbus, OH
Disclosure: Nothing to disclose
Christopher Ouellette, MD
Assistant Professor of Pediatrics
Nationwide Children's Hospital
Columbus, OH
Disclosure: Nothing to disclose
Background :
La Crosse Virus (LACV) is the most common neuroinvasive arboviral disease in children. Contemporary data on clinical presentation, management, outcomes, and predictors of disease severity are lacking.
Methods :
A retrospective analysis was performed of children (0-18yr) admitted to Nationwide Children’s Hospital from 1/2009-12/2018 diagnosed with LACV neuroinvasive disease (LACV-ND). LACV-ND diagnosis was defined as a compatible clinical illness and serum serologic detection of LACV in the absence of other infectious etiologies. Demographic, clinical, laboratory, electroencephalography (EEG), radiologic, and outcome data were recorded. Severe disease was defined as the presence of clinical or electroencephalographic status epilepticus, SIADH, PICU admission, mechanical ventilation (MV), parenteral/tube feeding, inpatient rehab, or intracranial pressure monitoring. Single variable and multivariate analyses were performed to determine factors predictive of disease severity.
Results : 140 patients, 76 (54%) males with a median age of 8 years [10mo-16yr], were identified with LACV-ND. Symptoms at presentation, laboratory abnormalities, EEG, radiography, and outcomes are shown in Table 1. 57 (41%) patients met criteria for severe disease, notably for PICU admission (n=41), status epilepticus (n=35), MV (n=13), and inpatient rehab (11). No in-patient deaths were observed. Exploratory analysis revealed that patients with severe disease were often younger at presentation, had higher rates of altered mental status (AMS), and seizures. Elevated serum white blood cell counts (WBC) and polymorphonuclear cell (PMN) predominance in serum and cerebrospinal fluid (CSF) were observed more frequently in severe disease. Multivariate analysis revealed presentation with seizures (OR 4.7 [95% CI 1.7-12.6], p=0.001), elevated serum WBC (OR 1.7 [95% CI 1.2-2.5], p=0.004), and a higher CSF PMN% (OR 1.03 [95% CI 1.01-1.06, p=0.003) to be independent predictors of severe disease.
Conclusion : At presentation, patients with severe disease tended to be younger, have greater rates of neurologic symptoms, and leukocytosis with PMN predominance in blood and CSF. These clinical and laboratory findings may serve as useful biomarkers to predict disease severity.
